Children with hypertrophic cardiomyopathy had significantly lower child-reported Cardiac module PedsQL scores compared to unaffected children attending for screening (72.3 vs 86.4; p<0.001).
Cross-Sectional (n=152)
What is the psychological well-being and quality of life in children with hypertrophic cardiomyopathy and those undergoing screening?
Children with hypertrophic cardiomyopathy have significantly reduced quality of life, whereas unaffected children undergoing screening have quality of life scores comparable to the normative population.
Absolute Event Rate: 72.3% vs 86.4%
p-value: p=<0.001
OBJECTIVE: This study aimed to assess the psychological well-being and quality of life in children with hypertrophic cardiomyopathy and the potential psychosocial impact of screening. METHODS: A total of 152 children (aged 3-18 years) attending a specialist paediatric hypertrophic cardiomyopathy clinic, and their parents completed the Generic Core Scales and Cardiac Module of the Paediatric Quality of Life Inventory (PedsQL) questionnaire as well as the Strengths and Difficulties Questionnaire; 21 patients (14%) had hypertrophic cardiomyopathy (group A); 23 children (15%) harboured hypertrophic cardiomyopathy-causing sarcomeric mutations with normal echocardiograms (group G); and 108 children (71%) had a family history of hypertrophic cardiomyopathy with normal investigations and attended for clinical cardiological screening (group S). RESULTS: In group A, mean PedsQLTM total scores reported by children and parents were lower than those reported by unaffected children (p<0.001). There was no significant difference between unaffected and gene-positive patients. Mean Cardiac module PedsQLTM total scores by children and parents were lower in children with hypertrophic cardiomyopathy compared with unaffected patients mean child-reported total score 86.4 in group S versus 72.3 in group A (p<0.001) and 80.2 in group G (p=0.25); mean parent-reported total score 91.6 in group S versus 71.4 in group A (p<0.001) and 87 in group G (p=0.4). There was no significant difference between group S and group G on any of the scales, or between the three groups of patients in the mean Strengths and Difficulties Questionnaire scores. CONCLUSIONS: Children with hypertrophic cardiomyopathy have a significantly reduced quality of life. Importantly, Quality-of-Life scores among unaffected children attending for screening were not different compared with scores from a normative UK population.
Spanaki et al. (2015) conducted a cross-sectional in Hypertrophic cardiomyopathy (n=152). Hypertrophic cardiomyopathy vs. Unaffected children attending for screening was evaluated on Mean Cardiac module PedsQL total score (child-reported) (p=<0.001). Children with hypertrophic cardiomyopathy had significantly lower child-reported Cardiac module PedsQL scores compared to unaffected children attending for screening (72.3 vs 86.4; p<0.001).